IONIS PHARMACEUTICALS INC

IONS

IONIS PHARMACEUTICALS INC

IONS

Insider Sentiment (TTM):

Last Purchase:2025-05-01Last Sale:2026-06-26Shares Purchased (TTM):0Shares Sold (TTM):2,066,054

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:158,758,340Shares Outstanding:164,874,000Institutional Ownership Pct.:96.29%

Earnings Market Reaction:

Filing Date:2026-07-29Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	350	173	372	338	297	264	242	335	294	349	399	352
Short Term Investments	1,705	1,746	2,305	1,902	1,993	1,881	2,056	2,149	1,785	1,857	1,932	1,884
Contract With Customer Asset Net Current	59	74	66	25	53	40	92	18	27	5	98	142
Inventory Net	51	6	10	10	8	12	13	28	29	30	7	26
Other Assets Current	327	306	237	244	226	223	218	184	195	174	205	181
Assets Current	2,491	2,937	2,991	2,519	2,577	2,419	2,620	2,714	2,329	2,416	2,642	2,585
Property Plant And Equipment Net	155	142	123	106	112	103	94	83	76	73	71	71
Operating Lease Right Of Use Asset	232	235	239	242	164	159	162	164	167	169	172	174
Other Assets Noncurrent	117	136	172	166	132	132	127	120	119	106	105	104
Assets	2,995	3,450	3,524	3,033	2,985	2,813	3,004	3,081	2,691	2,764	2,990	2,934
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	48	26	28	14	23	17	43	9	9	13	26	6
Employee Related Liabilities Current	50	36	116	57	47	27	70	41	35	22	68	34
Accrued Liabilities Current	116	127	106	99	99	103	108	124	114	106	148	119
Accrued Income Taxes Current	3	3	3	0	0	0	0	0	0	2	2	31
Convertible Debt Current	0	433	432	631	630	-	0	44	44	44	44	-
Contract With Customer Liability Current	74	69	74	77	76	81	79	76	94	130	151	205
Other Liabilities Current	25	23	23	25	23	22	9	10	9	10	9	10
Liabilities Current	316	717	782	903	897	250	309	305	306	328	448	404
Contract With Customer Liability Noncurrent	63	76	92	108	125	141	157	174	189	215	241	249
Operating Lease Liability Noncurrent	262	259	262	263	164	159	162	168	166	169	171	173
Long Term Loans From Bank	-	-	28	-	-	-	52	-	-	-	42	-
Other Liabilities Noncurrent	28	28	-	29	59	56	-	42	42	42	-	49
Liabilities	2,555	2,959	3,035	2,415	2,353	2,337	2,415	2,419	2,427	2,467	2,603	2,619
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	3,312	3,246	3,145	3,046	2,933	2,901	2,869	2,832	2,303	2,270	2,215	2,148
Accumulated Other Comprehensive Income Loss Net Of…	-34	-31	-25	-26	-28	-29	-31	-24	-35	-35	-33	-46
Retained Earnings Accumulated Deficit	-2,838	-2,724	-2,631	-2,402	-2,273	-2,397	-2,250	-2,145	-2,005	-1,939	-1,796	-1,787
Stockholders Equity	440	491	489	618	632	476	588	662	264	297	387	315
Liabilities And Stockholders Equity	2,995	3,450	3,524	3,033	2,985	2,813	3,004	3,081	2,691	2,764	2,990	2,934
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	300	300	300	300	300	300	300	300	300	300	300	300
Common Stock Shares Issued	166	166	163	161	159	159	158	158	146	146	144	143
Shares Outstanding	166	166	163	161	159	159	158	158	146	146	144	143

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	0.98%	-0.95%	-27.32%	-	-	-	-	-	-	-	-	-
2025	7.39%	21.82%	35.98%	-1.57%	40.67%	68.53%	5.86%	10.70%	6.19%	-11.92%	-6.07%	-7.90%
2024	-8.21%	16.44%	25.70%	-8.57%	-16.68%	-22.68%	-8.48%	-8.02%	-10.99%	3.62%	-12.29%	1.41%
2023	-	-	-	1.28%	13.43%	10.15%	13.95%	17.06%	16.58%	-2.25%	-4.11%	-10.22%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	7.89	4.10	3.83	2.79	2.87	9.66	8.47	8.91	7.61	7.37	5.90	6.39
Quick Ratio	7.73	4.09	3.81	2.78	2.86	9.62	8.43	8.82	7.51	7.28	5.88	6.33
Working Capital	2.18B	2.22B	2.21B	1.62B	1.68B	2.17B	2.31B	2.41B	2.02B	2.09B	2.19B	2.18B
Leverage & Debt
Debt to Equity	5.81	6.02	6.20	3.91	3.73	4.91	4.11	3.65	9.21	8.32	6.73	8.30
Interest Coverage TTM	-31.58	-19.23	-22.11	-16.72	-16.08	-27.87	-27.96	-21.34	-20.97	-25.59	-27.94	-56.51
Debt Ratio	0.85	0.86	0.86	0.80	0.79	0.83	0.80	0.78	0.90	0.89	0.87	0.89
Efficiency & Turnover
Asset Turnover TTM	0.29	0.34	0.29	0.32	0.33	0.26	0.24	0.27	0.29	0.27	0.29	0.23
Per Share Metrics
Diluted EPS TTM	-3.42	-1.98	-2.38	-1.60	-1.47	-2.89	-3.04	-2.41	-2.51	-2.64	-2.56	-2.86
Free Cash Flow Per Share TTM	-3.39	-5.89	-2.00	-1.89	-1.82	-3.50	-3.65	-2.51	-2.46	-2.36	-2.33	-3.97
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	98.17%	98.35%	98.31%	98.78%	98.89%	98.53%	98.41%	98.70%	98.58%	98.72%	98.84%	98.41%
Operating Profit Margin TTM	-68.00%	-33.29%	-40.45%	-28.75%	-28.23%	-65.87%	-67.37%	-46.12%	-44.87%	-50.10%	-44.91%	-90.34%
Net Profit Margin TTM	-64.66%	-30.90%	-40.41%	-26.51%	-28.41%	-63.86%	-64.37%	-44.68%	-44.96%	-49.54%	-46.50%	-66.57%
Growth Metrics
Net Revenue Growth (1Y)	-7.41%	47.53%	33.83%	20.41%	16.05%	-7.64%	-10.48%	30.57%	29.00%	34.84%	34.10%	-29.75%
Net Income Growth (1Y)	110.72%	-28.61%	-15.97%	-28.56%	-26.67%	19.04%	23.92%	-12.37%	18.35%	16.99%	35.80%	-5,692.86%
EPS Growth (1Y)	102.71%	-31.27%	-21.49%	-33.55%	-32.74%	9.14%	18.68%	-15.48%	16.03%	14.74%	34.53%	-5,639.51%
Valuation Metrics
P/E TTM	-23.21	-37.86	-33.19	-40.77	-23.44	-10.46	-11.52	-16.59	-19.02	-16.40	-19.78	-15.88
P/B TTM	29.83	25.19	25.88	16.91	9.95	10.07	8.88	8.99	26.38	21.28	18.73	20.61
P/S TTM	15.01	11.70	13.41	10.81	6.66	6.68	7.41	7.41	8.55	8.12	9.20	10.57
Market Cap	13.12B	12.38B	12.66B	10.45B	6.29B	4.79B	5.23B	5.95B	6.96B	6.31B	7.24B	6.50B
Enterprise Value	12.77B	12.64B	12.72B	10.74B	6.62B	4.52B	4.98B	5.66B	6.71B	6.00B	6.89B	6.15B
Calculated Values
Free Cash Flow TTM	-560.84M	-971.26M	-320.03M	-302.66M	-290.00M	-555.15M	-546.23M	-372.55M	-359.66M	-342.92M	-332.96M	-569.34M
Net Debt	-350.07M	259.12M	59.69M	292.57M	332.81M	-264.19M	-242.08M	-290.14M	-249.57M	-304.51M	-354.93M	-352.06M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-26Sale

Owner: Monia, Brett P

Title: Chief Executive Officer

Shares: 50,000

Price/Share: $80.59

Value: $4,029,500.00

Shares Owned: 245,571

Relationship: Director,Officer

Ownership: Direct

2026-06-26Sale

Owner: Schneider, Eugene

Title: EVP, Chf Clinical Develop Ofcr

Shares: 26,000

Price/Share: $81.05

Value: $2,107,300.00

Shares Owned: 77,114

Relationship: Officer

Ownership: Direct

2026-06-26Sale

Owner: O'Neil, Patrick R.

Title: EVP CLO & General Counsel

Shares: 3,069

Price/Share: $80.00

Value: $245,520.00

Shares Owned: 61,470

Relationship: Officer

Ownership: Direct

2026-06-26Sale

Owner: Baroldi, Joseph

Title: EVP, Chief Business Officer

Shares: 5,635

Price/Share: $80.16

Value: $451,701.60

Shares Owned: 4,669

Relationship: Officer

Ownership: Indirect

2026-06-25Sale

Owner: Swayze, Eric

Title: EVP Research

Shares: 10,602

Price/Share: $79.18

Value: $839,466.36

Shares Owned: 21,759

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-26	Monia, Brett P	Director,Officer	Chief Executive Officer	Direct	Sale	50,000	80.59	$4,029,500.00	245,571	4
2026-06-26	Schneider, Eugene	Officer	EVP, Chf Clinical Develop Ofcr	Direct	Sale	26,000	81.05	$2,107,300.00	77,114	4
2026-06-26	O'Neil, Patrick R.	Officer	EVP CLO & General Counsel	Direct	Sale	3,069	80.00	$245,520.00	61,470	4
2026-06-26	Baroldi, Joseph	Officer	EVP, Chief Business Officer	Indirect	Sale	5,635	80.16	$451,701.60	4,669	4
2026-06-25	Swayze, Eric	Officer	EVP Research	Direct	Sale	10,602	79.18	$839,466.36	21,759	4
2026-06-15	Berthelsen, Spencer R	Director	-	Direct	Sale	8,000	73.49	$587,920.00	156,013	4
2026-06-12	Kordasiewicz, Holly B.	Officer	EVP, Chief Development Officer	Direct	Sale	60,846	73.57	$4,476,440.22	22,458	4
2026-06-01	Berthelsen, Spencer R	Director	-	Direct	Sale	8,000	75.67	$605,360.00	156,013	4
2026-05-14	Monia, Brett P	Director,Officer	Chief Executive Officer	Direct	Sale	3,220	78.68	$253,349.60	242,662	4
2026-05-04	Loscalzo, Joseph	Director	-	Direct	Sale	77,289	75.24	$5,815,224.36	36,330	4
2026-05-01	Klein, Joseph Iii	Director	-	Direct	Sale	10,111	73.90	$747,202.90	11,014	4
2026-04-28	Baroldi, Joseph	Officer	EVP, Chief Business Officer	Direct	Sale	1,626	71.79	$116,730.54	44,909	4
2026-04-16	Jenne, Kyle	Officer	EVP, Chf GL Pdt Str Ofcr	Direct	Sale	4,902	75.17	$368,483.34	23,713	4
2026-04-16	Baroldi, Joseph	Officer	EVP, Chief Business Officer	Direct	Sale	5,619	74.56	$418,952.64	46,535	4
2026-04-16	Birchler, Brian	Officer	EVP, Corp and Development Ops	Direct	Sale	973	75.04	$73,013.92	67,500	4
2026-04-15	Parshall, B Lynne	Director	-	Direct	Sale	5,000	76.58	$382,900.00	51,344	4
2026-04-02	Devers, Shannon L.	Officer	EVP, Chief Human Resources Ofc	Direct	Sale	6,193	74.05	$458,591.65	16,348	4
2026-04-01	Klein, Joseph Iii	Director	-	Direct	Sale	22,321	75.72	$1,690,146.12	11,014	4
2026-03-19	Schneider, Eugene	Officer	EVP, Chf Clinical Develop Ofcr	Direct	Sale	5,812	70.97	$412,477.64	63,890	4
2026-03-17	Hougen, Elizabeth L	Officer	EVP, Finance & CFO	Direct	Sale	10,172	73.21	$744,692.12	82,660	4
2026-03-10	Jenne, Kyle	Officer	EVP, Chf GL Pdt Str Ofcr	Direct	Sale	37,277	75.90	$2,829,324.30	11,714	4
2026-03-10	Monia, Brett P	Director,Officer	Chief Executive Officer	Direct	Sale	34,103	75.90	$2,588,417.70	242,662	4
2026-03-09	O'Neil, Patrick R.	Officer	EVP CLO & General Counsel	Direct	Sale	10,148	75.25	$763,637.00	62,211	4
2026-03-04	Loscalzo, Joseph	Director	-	Direct	Sale	200	80.00	$16,000.00	36,330	4
2026-03-04	Baroldi, Joseph	Officer	EVP, Chief Business Officer	Indirect	Sale	439	80.00	$35,120.00	4,347	4
2026-03-03	Diaz, Allene M.	Director	-	Direct	Sale	54,878	79.93	$4,386,398.54	3,811	4
2026-03-03	Klein, Joseph Iii	Director	-	Direct	Sale	21,332	80.00	$1,706,560.00	11,014	4
2026-03-03	Devers, Shannon L.	Officer	EVP, Chief Human Resources Ofc	Direct	Sale	20,106	79.99	$1,608,278.94	22,541	4
2026-03-03	Bennett, C Frank	Officer	EVP, Chief Scientific Officer	Direct	Sale	85,089	79.91	$6,799,461.99	80,554	4
2026-02-13	Swayze, Eric	Officer	EVP Research	Direct	Sale	15,642	81.82	$1,279,828.44	32,105	4
2026-02-11	Parshall, B Lynne	Director	-	Direct	Sale	5,000	82.72	$413,600.00	56,344	4
2026-02-06	Monia, Brett P	Director,Officer	Chief Executive Officer	Direct	Sale	29,430	85.79	$2,524,799.70	254,497	4
2026-02-02	Bennett, C Frank	Officer	EVP, Chief Scientific Officer	Direct	Sale	85,089	82.89	$7,053,027.21	80,293	4
2026-01-30	Baroldi, Joseph	Officer	EVP, Chief Business Officer	Direct	Sale	5,296	82.96	$439,356.16	45,413	4
2026-01-30	Swayze, Eric	Officer	EVP Research	Direct	Sale	6,179	82.93	$512,424.47	47,747	4
2026-01-30	Hougen, Elizabeth L	Officer	EVP, Finance & CFO	Direct	Sale	6,988	83.24	$581,681.12	132,881	4
2026-01-30	Bennett, C Frank	Officer	EVP, Chief Scientific Officer	Direct	Sale	5,885	82.95	$488,160.75	100,293	4
2026-01-30	O'Neil, Patrick R.	Officer	EVP CLO & General Counsel	Direct	Sale	6,179	83.53	$516,131.87	71,983	4
2026-01-30	Monia, Brett P	Director,Officer	Chief Executive Officer	Direct	Sale	62,970	82.72	$5,208,878.40	283,927	4
2026-01-30	Schneider, Eugene	Officer	EVP, Chf Clinical Develop Ofcr	Direct	Sale	6,179	83.45	$515,637.55	69,702	4
2026-01-30	Birchler, Brian	Officer	EVP, Corp and Development Ops	Direct	Sale	6,179	83.03	$513,042.37	66,247	4
2026-01-22	Devers, Shannon L.	Officer	EVP, Chief Human Resources Ofc	Direct	Sale	3,977	81.34	$323,489.18	22,541	4
2026-01-16	Jenne, Kyle	Officer	EVP, Chf GL Pdt Str Ofcr	Direct	Sale	1,823	75.96	$138,475.08	16,389	4
2026-01-16	Bennett, C Frank	Officer	EVP, Chief Scientific Officer	Direct	Sale	8,977	75.15	$674,621.55	94,757	4
2026-01-16	Swayze, Eric	Officer	EVP Research	Direct	Sale	9,884	75.34	$744,660.56	41,935	4
2026-01-16	Devers, Shannon L.	Officer	EVP, Chief Human Resources Ofc	Direct	Sale	8,353	75.95	$634,410.35	26,518	4
2026-01-16	Kordasiewicz, Holly B.	Officer	EVP, Chief Development Officer	Direct	Sale	4,141	75.66	$313,308.06	14,718	4
2026-01-16	Monia, Brett P	Director,Officer	Chief Executive Officer	Direct	Sale	44,034	74.82	$3,294,623.88	224,683	4
2026-01-16	Baroldi, Joseph	Officer	EVP, Chief Business Officer	Direct	Sale	6,907	75.75	$523,205.25	40,431	4
2026-01-16	Hougen, Elizabeth L	Officer	EVP, Finance & CFO	Direct	Sale	12,922	75.22	$971,992.84	126,307	4
2026-01-16	O'Neil, Patrick R.	Officer	EVP CLO & General Counsel	Direct	Sale	9,191	75.84	$697,045.44	66,171	4
2026-01-16	Schneider, Eugene	Officer	EVP, Chf Clinical Develop Ofcr	Direct	Sale	9,302	75.59	$703,138.18	63,890	4
2026-01-16	Birchler, Brian	Officer	EVP, Corp and Development Ops	Direct	Sale	8,480	75.11	$636,932.80	60,435	4
2026-01-07	Devers, Shannon L.	Officer	EVP, Chief Human Resources Ofc	Direct	Sale	44,199	84.92	$3,753,379.08	17,494	4
2026-01-02	Swayze, Eric	Officer	EVP Research	Direct	Sale	23,463	78.92	$1,851,699.96	30,453	4
2025-12-01	Wender, Joseph H	Director	-	Indirect	Sale	28,000	80.95	$2,266,600.00	36,035	4
2025-11-25	Devers, Shannon L.	Officer	EVP, Chief Human Resources Ofc	Direct	Sale	16,777	80.91	$1,357,427.07	17,494	4
2025-11-25	Klein, Joseph Iii	Director	-	Indirect	Sale	12,000	80.00	$960,000.00	0	4
2025-11-19	Herman, Joan E	Director	-	Direct	Sale	44,000	72.13	$3,173,720.00	46,086	4
2025-11-06	Birchler, Brian	Officer	EVP, Corp and Development Ops	Direct	Sale	8,000	76.17	$609,360.00	48,826	4
2025-11-06	Geary, Richard S	Officer	EVP, Chief Development Officer	Direct	Sale	33,038	75.76	$2,502,958.88	59,657	4
2025-11-03	Geary, Richard S	Officer	EVP, Chief Development Officer	Direct	Sale	1,680	75.05	$126,084.00	59,657	4/A
2025-10-31	Loscalzo, Joseph	Director	-	Direct	Sale	16,000	75.10	$1,201,600.00	36,330	4
2025-10-31	Geary, Richard S	Officer	EVP, Chief Development Officer	Direct	Sale	89,249	75.11	$6,703,492.39	59,657	4
2025-10-31	Wender, Joseph H	Director	-	Indirect	Sale	11,200	75.16	$841,792.00	64,035	4
2025-10-16	Devers, Shannon L.	Officer	EVP, Chief Human Resources Ofc	Direct	Sale	1,263	73.62	$92,982.06	17,494	4
2025-10-16	Swayze, Eric	Officer	EVP Research	Indirect	Sale	53	73.62	$3,901.86	256	4
2025-10-15	Birchler, Brian	Officer	EVP, Corp and Development Ops	Direct	Sale	12,425	72.23	$897,457.75	56,826	4
2025-10-15	Parshall, B Lynne	Director	-	Direct	Sale	5,000	71.74	$358,700.00	61,344	4
2025-10-06	Baroldi, Joseph	Officer	EVP, Chief Business Officer	Direct	Sale	1,625	69.37	$112,726.25	30,301	4
2025-10-06	O'Neil, Patrick R.	Officer	EVP CLO & General Counsel	Direct	Sale	13,441	69.58	$935,224.78	53,889	4
2025-10-06	Swayze, Eric	Officer	EVP Research	Direct	Sale	6,849	69.02	$472,717.98	30,453	4
2025-10-06	Monia, Brett P	Director,Officer	Chief Executive Officer	Direct	Sale	437	69.26	$30,266.62	179,572	4
2025-10-02	Swayze, Eric	Officer	EVP Research	Direct	Sale	12,972	66.23	$859,135.56	37,302	4
2025-10-02	Baroldi, Joseph	Officer	EVP, Chief Business Officer	Direct	Sale	15,000	68.01	$1,020,150.00	31,926	4
2025-10-02	O'Neil, Patrick R.	Officer	EVP CLO & General Counsel	Direct	Sale	64,664	67.69	$4,377,106.16	57,130	4
2025-10-01	Wender, Joseph H	Director	-	Indirect	Sale	16,800	65.50	$1,100,400.00	92,035	4
2025-09-30	Hougen, Elizabeth L	Officer	EVP, Finance & CFO	Direct	Sale	49,800	65.26	$3,249,948.00	110,500	4
2025-09-30	Geary, Richard S	Officer	EVP, Chief Development Officer	Direct	Sale	57,900	65.24	$3,777,396.00	79,657	4
2025-09-30	O'Neil, Patrick R.	Officer	EVP CLO & General Counsel	Direct	Sale	14,827	64.68	$959,010.36	57,130	4
2025-09-12	O'Neil, Patrick R.	Officer	EVP CLO & General Counsel	Direct	Sale	1,700	64.58	$109,786.00	57,130	4
2025-09-09	Baroldi, Joseph	Officer	EVP, Chief Business Officer	Direct	Sale	11,950	62.16	$742,812.00	31,926	4
2025-09-09	O'Neil, Patrick R.	Officer	EVP CLO & General Counsel	Direct	Sale	21,000	64.56	$1,355,760.00	57,130	4
2025-09-05	Bennett, C Frank	Officer	EVP, Chief Scientific Officer	Direct	Sale	6,000	59.60	$357,600.00	82,679	4
2025-09-05	Baroldi, Joseph	Officer	EVP, Chief Business Officer	Direct	Sale	250	62.00	$15,500.00	31,926	4
2025-09-03	Loscalzo, Joseph	Director	-	Direct	Sale	16,000	60.15	$962,400.00	36,330	4
2025-09-03	Klein, Joseph Iii	Director	-	Indirect	Sale	28,000	60.00	$1,680,000.00	0	4
2025-09-03	Baroldi, Joseph	Officer	EVP, Chief Business Officer	Direct	Sale	32,800	60.55	$1,986,040.00	16,926	4
2025-09-03	Bennett, C Frank	Officer	EVP, Chief Scientific Officer	Direct	Sale	33,909	60.62	$2,055,563.58	101,570	4
2025-09-03	Monia, Brett P	Director,Officer	Chief Executive Officer	Direct	Sale	203,814	60.10	$12,249,221.40	180,009	4
2025-09-03	Wender, Joseph H	Director	-	Indirect	Sale	11,200	60.14	$673,568.00	108,835	4
2025-09-03	Schneider, Eugene	Officer	EVP, Chf Clinical Develop Ofcr	Direct	Sale	19,658	60.94	$1,197,958.52	51,507	4
2025-09-03	O'Neil, Patrick R.	Officer	EVP CLO & General Counsel	Direct	Sale	76,850	61.16	$4,700,146.00	5,655	4
2025-09-03	Devers, Shannon L.	Officer	EVP, Chief Human Resources Ofc	Direct	Sale	3,162	61.02	$192,945.24	15,009	4
2025-09-02	Parshall, B Lynne	Director	-	Direct	Sale	20,000	50.96	$1,019,200.00	66,344	4
2025-09-02	Swayze, Eric	Officer	EVP Research	Direct	Sale	11,130	51.45	$572,638.50	37,302	4
2025-09-02	Geary, Richard S	Officer	EVP, Chief Development Officer	Direct	Sale	10,000	50.37	$503,700.00	79,657	4
2025-08-22	Diaz, Allene M.	Director	-	Direct	Sale	1,427	42.53	$60,690.31	18,368	4
2025-08-18	Bennett, C Frank	Officer	EVP, Chief Scientific Officer	Direct	Sale	10,000	43.98	$439,800.00	93,466	4
2025-08-06	Parshall, B Lynne	Director	-	Direct	Sale	5,000	42.25	$211,250.00	86,344	4
2025-08-05	Geary, Richard S	Officer	EVP, Chief Development Officer	Direct	Sale	10,000	42.86	$428,600.00	89,492	4
2025-08-04	Schneider, Eugene	Officer	EVP, Chf Clinical Develop Ofcr	Direct	Sale	9,549	42.80	$408,697.20	51,507	4
2025-07-30	Monia, Brett P	Director,Officer	Chief Executive Officer	Direct	Sale	2,432	45.00	$109,440.00	179,820	4
2025-07-11	Monia, Brett P	Director,Officer	Chief Executive Officer	Direct	Sale	1,160	41.74	$48,418.40	179,820	4
2025-05-01	Hayden, Michael R	Director	-	Direct	Purchase	15,000	31.86	$477,900.00	50,219	4
2025-04-16	Birchler, Brian	Officer	EVP, Corp and Development Ops	Direct	Sale	680	28.37	$19,291.60	56,660	4
2025-04-16	Baroldi, Joseph	Officer	EVP, Chief Business Officer	Direct	Sale	3,928	28.40	$111,555.20	31,926	4
2025-04-16	Jenne, Kyle	Officer	EVP, Chf GL Pdt Str Ofcr	Direct	Sale	3,016	28.36	$85,533.76	11,199	4
2025-03-11	Monia, Brett P	Director,Officer	Chief Executive Officer	Direct	Sale	140	32.32	$4,524.80	180,980	4
2025-02-20	O'Neil, Patrick R.	Officer	EVP CLO & General Counsel	Direct	Sale	1,207	32.35	$39,046.45	56,245	4
2025-02-04	O'Neil, Patrick R.	Officer	EVP CLO & General Counsel	Direct	Sale	6,165	31.62	$194,937.30	57,452	4
2025-02-04	Monia, Brett P	Director,Officer	Chief Executive Officer	Direct	Sale	38,843	31.65	$1,229,380.95	180,683	4
2025-01-31	Swayze, Eric	Officer	EVP Research	Direct	Sale	1,367	32.31	$44,167.77	48,017	4
2025-01-31	Monia, Brett P	Director,Officer	Chief Executive Officer	Direct	Sale	13,242	32.45	$429,702.90	219,526	4
2025-01-31	Schneider, Eugene	Officer	EVP, Chf Clinical Develop Ofcr	Direct	Sale	1,484	32.20	$47,784.80	61,056	4
2025-01-31	Geary, Richard S	Officer	EVP, Chief Development Officer	Direct	Sale	1,406	32.40	$45,554.40	99,077	4
2025-01-31	O'Neil, Patrick R.	Officer	EVP CLO & General Counsel	Direct	Sale	1,406	32.49	$45,680.94	63,617	4
2025-01-31	Bennett, C Frank	Officer	EVP, Chief Scientific Officer	Direct	Sale	1,327	32.46	$43,074.42	93,146	4
2025-01-31	Hougen, Elizabeth L	Officer	EVP, Finance & CFO	Direct	Sale	1,523	32.44	$49,406.12	110,500	4
2025-01-16	Bennett, C Frank	Officer	EVP, Chief Scientific Officer	Direct	Sale	6,752	32.90	$222,140.80	90,866	4
2025-01-16	Monia, Brett P	Director,Officer	Chief Executive Officer	Direct	Sale	33,445	32.63	$1,091,310.35	207,396	4
2025-01-16	O'Neil, Patrick R.	Officer	EVP CLO & General Counsel	Direct	Sale	7,360	32.83	$241,628.80	61,203	4
2025-01-16	Devers, Shannon L.	Officer	EVP, Chief Human Resources Ofc	Direct	Sale	4,267	32.78	$139,872.26	15,937	4
2025-01-16	Schneider, Eugene	Officer	EVP, Chf Clinical Develop Ofcr	Direct	Sale	6,523	32.79	$213,889.17	58,508	4
2025-01-16	Swayze, Eric	Officer	EVP Research	Direct	Sale	7,154	32.84	$234,937.36	45,670	4
2025-01-16	Baroldi, Joseph	Officer	EVP, Chief Business Officer	Direct	Sale	3,401	32.70	$111,212.70	25,017	4
2025-01-16	Hougen, Elizabeth L	Officer	EVP, Finance & CFO	Direct	Sale	8,870	32.81	$291,024.70	107,885	4
2025-01-16	Geary, Richard S	Officer	EVP, Chief Development Officer	Direct	Sale	7,072	32.86	$232,385.92	96,663	4
2025-01-16	Birchler, Brian	Officer	EVP, Corp and Development Ops	Direct	Sale	5,400	32.70	$176,580.00	55,051	4
2024-12-23	Hayden, Michael R	Director	-	Direct	Purchase	5,000	36.22	$181,100.00	35,219	4
2024-11-12	Monia, Brett P	Director,Officer	Chief Executive Officer	Direct	Sale	6,630	38.05	$252,271.50	167,393	4
2024-11-12	Swayze, Eric	Officer	EVP Research	Direct	Sale	1,194	37.92	$45,276.48	33,713	4
2024-11-12	Loscalzo, Joseph	Director	-	Direct	Sale	13,508	37.86	$511,412.88	32,251	4
2024-10-16	Swayze, Eric	Officer	EVP Research	Indirect	Sale	53	38.31	$2,030.43	157	4
2024-08-29	Geary, Richard S	Officer	EVP, Chief Development Officer	Direct	Sale	331	49.63	$16,427.53	84,823	4
2024-08-05	Geary, Richard S	Officer	EVP, Chief Development Officer	Direct	Sale	2,430	48.00	$116,640.00	85,508	4
2024-07-16	Diaz, Allene M.	Director	-	Direct	Sale	1,637	49.56	$81,129.72	15,716	4
2024-07-16	Klein, Joseph Iii	Director	-	Indirect	Sale	12,000	50.00	$600,000.00	0	4
2024-06-17	Berthelsen, Spencer R	Director	-	Direct	Sale	16,000	40.29	$644,640.00	147,257	4
2024-05-03	Klein, Joseph Iii	Director	-	Indirect	Sale	6,000	42.76	$256,560.00	0	4
2024-04-16	Birchler, Brian	Officer	EVP, Corp and Development Ops	Direct	Sale	905	41.66	$37,702.30	46,156	4
2024-04-16	Baroldi, Joseph	Officer	EVP, Chief Business Officer	Direct	Sale	4,006	41.60	$166,649.60	19,631	4
2024-02-16	Monia, Brett P	Director,Officer	Chief Executive Officer	Direct	Sale	387	44.49	$17,217.63	173,751	4
2024-02-02	Bennett, C Frank	Officer	EVP, Chief Scientific Officer	Direct	Sale	1,885	49.52	$93,345.20	79,047	4/A
2024-02-02	Geary, Richard S	Officer	EVP, Chief Development Officer	Direct	Sale	1,995	50.04	$99,829.80	87,300	4/A
2024-02-02	Swayze, Eric	Officer	EVP Research	Direct	Sale	1,940	49.56	$96,146.40	34,291	4/A
2024-02-02	Monia, Brett P	Director,Officer	Chief Executive Officer	Direct	Sale	23,907	49.37	$1,180,288.59	173,732	4/A
2024-02-02	Monia, Brett P	Director,Officer	Chief Executive Officer	Direct	Sale	23,501	49.37	$1,160,244.37	174,138	4
2024-02-02	Hougen, Elizabeth L	Officer	EVP, Finance & CFO	Direct	Sale	2,162	49.54	$107,105.48	92,868	4/A
2024-02-02	Hougen, Elizabeth L	Officer	EVP, Finance & CFO	Direct	Sale	2,125	49.54	$105,272.50	92,905	4
2024-02-02	Geary, Richard S	Officer	EVP, Chief Development Officer	Direct	Sale	1,961	50.04	$98,128.44	87,334	4
2024-02-02	Schneider, Eugene	Officer	EVP, Chf Clinical Develop Ofcr	Direct	Sale	2,071	49.59	$102,700.89	49,812	4
2024-02-02	Cadoret-Manier, Onaiza	Officer	EVP, Chf GL Pdt Str & Oper Ofc	Direct	Sale	2,125	49.60	$105,400.00	35,825	4
2024-02-02	Bennett, C Frank	Officer	EVP, Chief Scientific Officer	Direct	Sale	1,853	49.52	$91,760.56	79,079	4
2024-02-02	O'Neil, Patrick R.	Officer	EVP CLO & General Counsel	Direct	Sale	1,961	49.67	$97,402.87	48,661	4
2024-02-02	Schneider, Eugene	Officer	EVP, Chf Clinical Develop Ofcr	Direct	Sale	2,106	49.59	$104,436.54	47,659	4/A
2024-02-02	Swayze, Eric	Officer	EVP Research	Direct	Sale	1,907	49.56	$94,510.92	34,324	4
2024-02-02	O'Neil, Patrick R.	Officer	EVP CLO & General Counsel	Direct	Sale	1,995	49.67	$99,091.65	48,627	4/A
2024-02-02	Cadoret-Manier, Onaiza	Officer	EVP,Chf GL Pdt Str & Oper Ofc	Direct	Sale	2,162	49.60	$107,235.20	35,788	4/A
2024-01-25	Monia, Brett P	Director,Officer	Chief Executive Officer	Direct	Sale	2,285	51.75	$118,248.75	151,851	4
2024-01-25	O'Neil, Patrick R.	Officer	EVP CLO & General Counsel	Direct	Sale	6,450	51.75	$333,787.50	46,802	4
2024-01-17	Schneider, Eugene	Officer	EVP, Chf Clinical Develop Ofcr	Direct	Sale	5,482	50.42	$276,402.44	47,850	4
2024-01-17	Geary, Richard S	Officer	EVP, Chief Development Officer	Direct	Sale	7,338	50.42	$369,981.96	85,475	4
2024-01-17	Baroldi, Joseph	Officer	EVP, Chief Business Officer	Direct	Sale	1,460	50.42	$73,613.20	12,799	4
2024-01-17	Cadoret-Manier, Onaiza	Officer	EVP, Chf GL Pdt Str & Oper Ofc	Direct	Sale	5,564	50.42	$280,536.88	33,810	4
2024-01-17	Monia, Brett P	Director,Officer	Chief Executive Officer	Direct	Sale	32,059	50.42	$1,616,414.78	154,136	4
2024-01-17	Swayze, Eric	Officer	EVP Research	Direct	Sale	6,296	50.42	$317,444.32	43,289	4
2024-01-17	O'Neil, Patrick R.	Officer	EVP CLO & General Counsel	Direct	Sale	7,744	50.42	$390,452.48	53,252	4
2024-01-17	Birchler, Brian	Officer	EVP, Corp and Development Ops	Direct	Sale	4,497	50.42	$226,738.74	44,582	4
2024-01-17	Bennett, C Frank	Officer	EVP, Chief Scientific Officer	Direct	Sale	6,745	50.42	$340,082.90	77,323	4
2024-01-17	Hougen, Elizabeth L	Officer	EVP, Finance & CFO	Direct	Sale	8,683	50.42	$437,796.86	90,890	4
2024-01-12	Schneider, Eugene	Officer	EVP, Chf Clinical Develop Ofcr	Direct	Sale	8,000	53.50	$428,000.00	38,170	4
2023-12-28	Swayze, Eric	Officer	EVP Research	Direct	Sale	27,100	50.19	$1,360,149.00	32,516	4
2023-12-28	Parshall, B Lynne	Director	-	Direct	Sale	42,525	50.19	$2,134,329.75	82,588	4
2023-12-26	O'Neil, Patrick R.	Officer	EVP CLO & General Counsel	Direct	Sale	20,825	51.46	$1,071,654.50	40,355	4
2023-12-26	Schneider, Eugene	Officer	EVP, Chf Clinical Develop Ofcr	Direct	Sale	25,000	51.46	$1,286,500.00	36,052	4
2023-12-21	Monia, Brett P	Director,Officer	Chief Executive Officer	Direct	Sale	17,500	49.29	$862,575.00	118,111	4
2023-12-21	Bennett, C Frank	Officer	EVP, Chief Scientific Officer	Direct	Sale	16,113	49.29	$794,209.77	65,754	4
2023-12-21	Geary, Richard S	Officer	EVP, Chief Development Officer	Direct	Sale	4,112	49.29	$202,680.48	72,961	4
2023-12-14	Bennett, C Frank	Officer	EVP, Chief Scientific Officer	Direct	Sale	22,612	49.70	$1,123,816.40	65,754	4
2023-12-14	Geary, Richard S	Officer	EVP, Chief Development Officer	Direct	Sale	10,613	49.70	$527,466.10	72,961	4
2023-12-14	Monia, Brett P	Director,Officer	Chief Executive Officer	Direct	Sale	24,000	49.70	$1,192,800.00	118,111	4
2023-11-15	Klein, Joseph Iii	Director	-	Direct	Sale	2,000	50.00	$100,000.00	16,346	4
2023-10-17	Swayze, Eric	Officer	EVP Research	Indirect	Sale	52	47.95	$2,493.40	73	4
2023-10-12	Monia, Brett P	Director,Officer	Chief Executive Officer	Direct	Sale	3,770	46.00	$173,420.00	118,111	4
2023-09-28	Bennett, C Frank	Officer	EVP, Chief Scientific Officer	Direct	Sale	4,460	46.50	$207,390.00	65,754	4
2023-09-26	Parshall, B Lynne	Director	-	Direct	Sale	10,000	45.13	$451,300.00	82,588	4
2023-09-26	Klein, Joseph Iii	Director	-	Direct	Sale	2,000	45.13	$90,260.00	18,346	4
2023-08-01	Diaz, Allene M.	Director	-	Direct	Sale	657	41.05	$26,969.85	12,676	4
2023-07-18	Klein, Joseph Iii	Director	-	Direct	Sale	3,555	42.00	$149,310.00	20,346	4
2023-07-07	Monia, Brett P	Director,Officer	Chief Executive Officer	Direct	Sale	18,650	42.25	$787,962.50	121,724	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

96.29%

Inst. Shares: 158,758,340

Shares Outstanding: 164,874,000

2025-12-31

96.92%

Inst. Shares: 155,075,344

Shares Outstanding: 160,010,000

2025-09-30

93.64%

Inst. Shares: 149,596,414

Shares Outstanding: 159,765,000

2025-06-30

92.07%

Inst. Shares: 146,519,609

Shares Outstanding: 159,137,000

2025-03-31

90.48%

Inst. Shares: 143,616,107

Shares Outstanding: 158,735,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	158,758,340	164,874,000	96.29%
2025-12-31	155,075,344	160,010,000	96.92%
2025-09-30	149,596,414	159,765,000	93.64%
2025-06-30	146,519,609	159,137,000	92.07%
2025-03-31	143,616,107	158,735,000	90.48%
2024-12-31	138,962,786	149,514,000	92.94%
2024-09-30	134,185,078	148,593,000	90.30%
2024-06-30	123,615,142	145,958,000	84.69%
2024-03-31	120,582,607	145,538,000	82.85%
2023-12-31	121,393,860	143,190,000	84.78%
2023-09-30	117,177,404	143,317,000	81.76%
2023-06-30	108,233,864	143,098,000	75.64%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

IONIS PHARMACEUTICALS INC (IONS) — SEC Financial Statements & Analysis

IONIS PHARMACEUTICALS INC (IONS) is a pharmaceutical preparations company, incorporated in CA. IONIS PHARMACEUTICALS INC trades on Nasdaq as: IONS. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), IONIS PHARMACEUTICALS INC reported a -7.41% year-over-year revenue growth, a Gross Profit Margin of 98.17% (TTM), a Debt-to-Equity ratio of 5.81x, a Price-to-Sales (P/S) ratio of 15.01x (TTM), a Price-to-Book (P/B) ratio of 29.83x (TTM), at a market cap of $13.12B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -7.41%
Gross Profit Margin TTM: 98.17%
Debt To Equity: 5.81x
P/S TTM: 15.01x
P/B TTM: 29.83x
Market Cap: $13.12B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is IONIS PHARMACEUTICALS INC in?

IONIS PHARMACEUTICALS INC (IONS) operates in the Pharmaceutical Preparations industry.

What is IONS's market cap?

IONIS PHARMACEUTICALS INC (IONS) has a market capitalization of $13.12B as of 2026-06-30.

What exchange does IONS trade on?

IONIS PHARMACEUTICALS INC (IONS) trades on the Nasdaq.

Where is IONIS PHARMACEUTICALS INC incorporated?

IONIS PHARMACEUTICALS INC is incorporated in CA.